Return to homepagePandemic Pact

AfriCoVER: Characterising transmission parameters of SARS-CoV-2 in peri-urban setting in Mozambique using population-based surveillance and high-throughput sero-assay

  • Funded by European & Developing Countries Clinical Trials Partnership (EDCTP)
  • Total publications:4 publications

Grant number: RIA2020EF-3031

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    2020

  • Known Financial Commitments (USD)

    $554,988.9

  • Funder

    European & Developing Countries Clinical Trials Partnership (EDCTP)

  • Principal Investigator

    Dr. Marc-Alain Widdowson

  • Research Location

    Mozambique

  • Lead Research Institution

    Prins Leopold Instituut voor Tropische Geneeskunde (ITM)

  • Research Priority Alignment

    N/A

  • Research Category

    Epidemiological studies

  • Research Subcategory

    Disease transmission dynamics

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The AfriCoVER project (RIA2020EF-3031) aims to conduct population-based surveillance in a Demographic Health Surveillance System (HDSS) of 16,500 people in a peri-urban neighbourhood of Maputo, Mozambique, by collecting clinical information and respiratory specimens from patients during biweekly household visits, complemented with data from local clinics.

Publicationslinked via Europe PMC

Last Updated:14 hours ago

View all publications at Europe PMC

Embedding risk monitoring in infectious disease surveillance for timely and effective outbreak prevention and control.

Mild and moderate COVID-19 during Alpha, Delta and Omicron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: A population-based surveillance study.

Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2.

Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay.